It looks easier now because we have a viable product to sell, and a product that we can improve and expand on.
As for date, I wouldn't want to put a date on it, but a few numbers to consider about:
- Ellume aims to produce about 250m tests per year
- Quidel aims to produce about 600m tests per year
- Abbott sold 300m tests in 4th quarter CY in 2020, generated $2.4b of revenue
- There are 748m people in Europe, 1.3b people in India, 332m in the US
- Around 50m people is affected by Sepsis every year, 11m people dies from it, 1 death every 2.8 seconds
- Operon has capacity for 8m completed test per year, and additional 20m strips they can produce
- Operon aims to triple its capacity by 2023 (8m x 3 = 24m)
For $5.00 per share, we just need $500m profit (at PE of 20) per year (probably shouldn't use the word 'just', but compare to competitors' numbers, you can see what numbers can be achieved).
- Forums
- ASX - By Stock
- ADO
- Ann: Update - AnteoTech signs manufacturing contract with Operon
Ann: Update - AnteoTech signs manufacturing contract with Operon, page-165
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ADO (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $59.24M |
Open | High | Low | Value | Volume |
2.3¢ | 2.4¢ | 2.2¢ | $42.79K | 1.848M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 271944 | 2.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.4¢ | 851994 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 271944 | 0.023 |
4 | 527436 | 0.022 |
4 | 1096532 | 0.021 |
9 | 1128501 | 0.020 |
7 | 1044605 | 0.019 |
Price($) | Vol. | No. |
---|---|---|
0.024 | 851994 | 5 |
0.025 | 1110470 | 11 |
0.026 | 891415 | 5 |
0.027 | 250000 | 1 |
0.028 | 250000 | 1 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
ADO (ASX) Chart |